Free 1-hr "Live" CME/AAPA/CNE/CPE/CPT/CPH Webinar on: Role of FDA and ISMP in Preventing Medication Errors - Drug Information Update

FDA’s Division of Drug Information is presenting a series of continuing education webinars targeting the needs of all health care professionals.

FDA Drug Topics: Role of FDA and ISMP in Preventing Medication Errors Will be held on: March 17, 2020 Time: 1:00 pm to 2:00 pm (EST) To register for the online meeting, please visit: http://collaboration.fda.gov/ddi031720/event/registration.html After registering, you will receive a calendar invitation with details on how to join the online meeting.

Activity Outline Description: This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety. This webinar will describe the role of the Division of Medication Error Prevention and Analysis (DMEPA) in preventing and addressing medication errors through pre-market and post-market activities. DMEPA also collaborates with external stakeholders, such as the nonprofit Institute for Safe Medication Practices (ISMP), a federally authorized patient safety organization (PSO). The webinar will illustrate how information from the ISMP National Medication Errors Reporting Program is shared with FDA in a way that benefits overall drug safety. Actions taken to address recent medication error reports will be explored, as well as the role of pharmacists in identifying, preventing and mitigating medication errors.  Series Objectives: Explain how to utilize FDA’s drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes. Describe and inform health care providers of recent labeling changes which would impact prescribing and medication management to optimize patient care. References: Draft Guidance for Industry: Best Practices in Developing Proprietary Names for Drugs: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-developing-proprietary-names-drugs.   Draft Guidance for Industry: Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-container-labels-and-carton-labeling-design-minimize-medication-errors. Guidance for Industry: Safety Considerations for Product Design to Minimize Medication Errors: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-product-design-minimize-medication-errors-guidance-industry. Guidance for Industry: Applying Human Factors and Usability Engineering to Medical Devices: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices.   A Lot Happens When You Report a Hazard or Error to ISMP – There’s No “Black Hole” Here!: https://www.ismp.org/acute-care/medication-safety-alert-november-7-2019. ISMP. Start the New Year Off Right by Preventing These Top 10 Medication Errors and Hazards: https://www.ismp.org/acute-care/medication-safety-alert-january-16-2020.  Learning Objectives: After completion of this activity, the participant will be able to: Describe FDA’s role in pre-marketing and post-marketing activities to prevent and address medication errors. Outline strategies aimed to increase the safe use of drug products by minimizing use error that is related to the design, naming, labeling, and/or packaging of drug products. Review examples of recent medication error reports. Summarize how HCPs can help identify, prevent, and mitigate medication errors.  Target Audience: This activity is intended for physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students.  Schedule: 1:00 pm - 2:00 pm – FDA Drug Topics: Role of FDA and ISMP in Preventing Medication Errors, presented by Mishale Mistry, PharmD, MPH, Associate Director in FDA/CDER/Division of Medication Error Prevention and Analysis (DMEPA) and Michael R. Cohen, RPh, MS, ScD (hon.), DPS (hon.), FASHP, President of The Institute for Safe Medication Practices (ISMP), a non-profit patient safety organization (PSO).

Continuing Education: Accreditation:

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians and physician assistants should claim only the credit commensurate with the extent of their participation in the activity. CPE This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-20-025-L05-P, and ACPE Universal Activity Number JA0002895-0000-20-025-L05-T for 1.00 contact hour(s). CNE FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

AAPA

This activity is designated for 1.00 AAPA Category 1 CME credits. FDA Center for Drug Evaluation and Research has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

CPH Up to 1.00 CPH Recertification Credits may be earned at this event. Requirements for receiving CE Credit: Physicians, physician assistants, nurses, pharmacists, pharmacy technicians, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation survey via the CE Portal (ceportal.fda.gov). Final activity evaluations must be completed within two weeks after the activity - no exceptions. Pharmacy participants: Pharmacists and pharmacy technicians will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.   Important Note regarding completion of evaluations and receiving credit: Attendees have 14 days from the last day of the activity to log in, attest to your attendance, and complete the required evaluation survey, to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the activity to obtain their CE credit. Disclosure: Faculty: Cohen, Michael, RPh, President, ISMP - nothing to disclose Mistry, Mishale, PharmD, Associate Director, FDA - nothing to disclose Planning Committee: Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose Cao, Christian, MPAS, PA-C, Safety Evaluator Team Leader, FDA/CDER/OSE/DPV - nothing to disclose DeFronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose Kapoor, Rama, MD, Medical Officer, FDA - nothing to disclose Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose       CE Consultation and Accreditation Team: Thompson, Lisa, MSHA, MBA, CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose Registration Fees and Refunds: Registration is complimentary therefore refunds are not applicable. Please direct your comments or questions via email to DDIWebinars@fda.hhs.gov. To learn more about future dates and registration, please visit: www.fda.gov/DDIWebinars.